Researchers from Yale School of Medicine, along with Helsinki University Hospital and University of Helsinki, have reported data from a study that aimed to assess the effects of a common variant in hydroxysteroid 17-β dehydrogenase 13 (HSD17B13 rs72613567-A) in the liver.